FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017047836> ?p ?o ?g. }

• W2017047836 endingPage "1051" @default.
• W2017047836 startingPage "1045" @default.
• W2017047836 abstract "This review focuses on the promising roles of prostate secretory protein of 94 amino acids (PSP-94) and one of its derived peptides (PCK3145) as potential therapeutic modalities for prostate cancer and its associated complications. Evaluation of these compounds was carried out in vitro and in vivo using syngeneic models of rat prostate cancer. Overproduction of parathyroid hormone-related protein (PTHrP) results in the development of hypercalcemia of malignancy in several malignancies including prostate cancer. In order to evaluate the effect of PSP-94 and PCK3145 on prostate cancer progression, the rat Dunning R3227 MatLyLu cell line transfected with full-length cDNA encoding PTHrP (MatLyLu-PTHrP) was used. As the main pathogenetic factor of hypercalcemia of malignancy, overexpression of PTHrP was aimed at mimicking the hypercalcemic nature seen in patients suffering from late-stage cancer. In vitro studies showed that PSP-94 and PCK3145 can cause a dose-dependent inhibition in the growth of MatLyLu-PTHrP cells. For in vivo studies, male Copenhagen rats were inoculated either s.c. into the right flank or directly into the left ventricle via intracardiac (i.c.) inoculation with MatLyLu-PTHrP cells. In these models, s.c. injection of MatLyLu cells results in the development of primary tumor growth, whereas i.c. inoculation routinely results in the development of experimental skeletal metastases in the lumbar vertebrae causing hind-limb paralysis. Administration of PSP-94 and PCK3145 into tumor-bearing animals resulted in a dose-dependent inhibition of primary tumor growth, and tumoral and plasma PTHrP levels, and in the reduction of plasma calcium levels. Additionally, treatment with PSP-94 or PCK3145 caused an inhibition of skeletal metastases resulting in a significant delay in the development of hind-limb paralysis. Interestingly, equimolar concentrations of PCK3145 were shown to be more effective in delaying the development of experimental skeletal metastases as compared to PSP-94. One of the possible mechanisms of action of these modalities is through the induction of apoptosis which was observed by both in-vitro and in-vivo analyses of MatLyLu-PTHrP cells and tumors. Several intracellular mechanisms can also be involved in inhibiting PTHrP production and anti-tumor effects of PSP-94 and PCK3145. Collectively, these studies warrant the continued clinical development of these agents as therapeutic agents for patients with hormone-refractory prostate cancer." @default.
• W2017047836 created "2016-06-24" @default.
• W2017047836 creator A5038683160 @default.
• W2017047836 creator A5046480395 @default.
• W2017047836 creator A5051435795 @default.
• W2017047836 creator A5077821035 @default.
• W2017047836 creator A5078109857 @default.
• W2017047836 date "2005-11-01" @default.
• W2017047836 modified "2023-10-16" @default.
• W2017047836 title "Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer" @default.
• W2017047836 cites W1500814995 @default.
• W2017047836 cites W1670027677 @default.
• W2017047836 cites W1965918908 @default.
• W2017047836 cites W1968231448 @default.
• W2017047836 cites W1971544338 @default.
• W2017047836 cites W1972138927 @default.
• W2017047836 cites W1979362121 @default.
• W2017047836 cites W1980881175 @default.
• W2017047836 cites W1991486724 @default.
• W2017047836 cites W1998580928 @default.
• W2017047836 cites W2001544310 @default.
• W2017047836 cites W2003843932 @default.
• W2017047836 cites W2005658600 @default.
• W2017047836 cites W2009364828 @default.
• W2017047836 cites W2010461405 @default.
• W2017047836 cites W2013466049 @default.
• W2017047836 cites W2017211434 @default.
• W2017047836 cites W2021017012 @default.
• W2017047836 cites W2028373666 @default.
• W2017047836 cites W2028853380 @default.
• W2017047836 cites W2029628988 @default.
• W2017047836 cites W2037383755 @default.
• W2017047836 cites W2038079572 @default.
• W2017047836 cites W2041418516 @default.
• W2017047836 cites W2047217306 @default.
• W2017047836 cites W2053243641 @default.
• W2017047836 cites W2059972525 @default.
• W2017047836 cites W2070259427 @default.
• W2017047836 cites W2073579996 @default.
• W2017047836 cites W2083583090 @default.
• W2017047836 cites W2084483973 @default.
• W2017047836 cites W2085691330 @default.
• W2017047836 cites W2100058173 @default.
• W2017047836 cites W2120893462 @default.
• W2017047836 cites W2130856648 @default.
• W2017047836 cites W2137302120 @default.
• W2017047836 cites W2139222206 @default.
• W2017047836 cites W2164934175 @default.
• W2017047836 cites W2168478740 @default.
• W2017047836 cites W2168848424 @default.
• W2017047836 cites W2316880140 @default.
• W2017047836 cites W2324598527 @default.
• W2017047836 cites W2412431453 @default.
• W2017047836 cites W2417945703 @default.
• W2017047836 cites W2809089305 @default.
• W2017047836 cites W39354950 @default.
• W2017047836 doi "https://doi.org/10.1097/00001813-200511000-00002" @default.
• W2017047836 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16222145" @default.
• W2017047836 hasPublicationYear "2005" @default.
• W2017047836 type Work @default.
• W2017047836 sameAs 2017047836 @default.
• W2017047836 citedByCount "13" @default.
• W2017047836 countsByYear W20170478362016 @default.
• W2017047836 countsByYear W20170478362018 @default.
• W2017047836 countsByYear W20170478362021 @default.
• W2017047836 crossrefType "journal-article" @default.
• W2017047836 hasAuthorship W2017047836A5038683160 @default.
• W2017047836 hasAuthorship W2017047836A5046480395 @default.
• W2017047836 hasAuthorship W2017047836A5051435795 @default.
• W2017047836 hasAuthorship W2017047836A5077821035 @default.
• W2017047836 hasAuthorship W2017047836A5078109857 @default.
• W2017047836 hasConcept C121608353 @default.
• W2017047836 hasConcept C126322002 @default.
• W2017047836 hasConcept C134018914 @default.
• W2017047836 hasConcept C142724271 @default.
• W2017047836 hasConcept C150903083 @default.
• W2017047836 hasConcept C207001950 @default.
• W2017047836 hasConcept C2776235491 @default.
• W2017047836 hasConcept C2779399171 @default.
• W2017047836 hasConcept C2780192828 @default.
• W2017047836 hasConcept C502942594 @default.
• W2017047836 hasConcept C71924100 @default.
• W2017047836 hasConcept C86803240 @default.
• W2017047836 hasConceptScore W2017047836C121608353 @default.
• W2017047836 hasConceptScore W2017047836C126322002 @default.
• W2017047836 hasConceptScore W2017047836C134018914 @default.
• W2017047836 hasConceptScore W2017047836C142724271 @default.
• W2017047836 hasConceptScore W2017047836C150903083 @default.
• W2017047836 hasConceptScore W2017047836C207001950 @default.
• W2017047836 hasConceptScore W2017047836C2776235491 @default.
• W2017047836 hasConceptScore W2017047836C2779399171 @default.
• W2017047836 hasConceptScore W2017047836C2780192828 @default.
• W2017047836 hasConceptScore W2017047836C502942594 @default.
• W2017047836 hasConceptScore W2017047836C71924100 @default.
• W2017047836 hasConceptScore W2017047836C86803240 @default.
• W2017047836 hasIssue "10" @default.
• W2017047836 hasLocation W20170478361 @default.
• W2017047836 hasLocation W20170478362 @default.

• next